Early triple antiviral therapy for COVID-19
Open Access
- 1 November 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 396 (10261), 1487-1488
- https://doi.org/10.1016/s0140-6736(20)32274-1
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Pharmacologic Treatments and Supportive Care for Middle East Respiratory SyndromeEmerging Infectious Diseases, 2020
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialThe Lancet, 2020
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational StudyClinical Infectious Diseases, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020